

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:		NEW ASSIGNMENT	
NATURE OF CONVEYANCE:		ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL	
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
PHARMACIA & UPJOHN COMPANY		04/16/2009	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	PHIVCO-2 LLC		
Street Address:	Corporation Service Company		
Internal Address:	2711 Centerville Road Suite 400		
City:	Wilmington		
State/Country:	DELAWARE		
Postal Code:	19808		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	1926253	RESCRIPTOR	
CORRESPONDENCE DATA			
Fax Number:	(704)625-9190		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	919 483 1803		
Email:	trademarks@gsk.com		
Correspondent Name:	Maribeth Day Case		
Address Line 1:	Five Moore Drive		
Address Line 2:	LGTM, C.3157.3D		
Address Line 4:	Research Triangle Pa, NORTH CAROLINA 27709		
ATTORNEY DOCKET NUMBER:	PRJ-COA/7041330/084/PDJ		
NAME OF SUBMITTER:	Maribeth Day Case		
Signature:	/Maribeth Day Case/		

CH \$40.00 1926253

Date:

07/14/2011

Total Attachments: 15

source=PHIVCO-2 LLC Assignment#page1.tif
source=PHIVCO-2 LLC Assignment#page2.tif
source=PHIVCO-2 LLC Assignment#page3.tif
source=PHIVCO-2 LLC Assignment#page4.tif
source=PHIVCO-2 LLC Assignment#page5.tif
source=PHIVCO-2 LLC Assignment#page6.tif
source=PHIVCO-2 LLC Assignment#page7.tif
source=PHIVCO-2 LLC Assignment#page8.tif
source=PHIVCO-2 LLC Assignment#page9.tif
source=PHIVCO-2 LLC Assignment#page10.tif
source=PHIVCO-2 LLC Assignment#page11.tif
source=PHIVCO-2 LLC Assignment#page12.tif
source=PHIVCO-2 LLC Assignment#page13.tif
source=PHIVCO-2 LLC Assignment#page14.tif
source=PHIVCO-2 LLC Assignment#page15.tif

IP ASSIGNMENT

WHEREAS, those parties listed in Appendix B (each an "Assignor") owns certain rights in (A) the patents and patent applications each listed on Part 1 of Appendix A and (B) the trade marks and trade mark applications each listed on Part 2 of Appendix A (whether or not any of these is registered) and in each case including applications and rights to apply for registration of any such thing) (each of (A) and (B) the "Intellectual Property Rights"); and

WHEREAS, on April 16, 2009 Pfizer Inc. ("Pfizer"), GlaxoSmithKline plc ("GSK") and GlaxoSmithKline Newco Limited ("Mercury") entered into a Share Purchase Agreement ("the SPA Agreement") in connection with the proposed joint venture between Pfizer and GSK to create a new specialist company dedicated to the research, development and commercialization of HIV medicines (the "Transaction"); and

WHEREAS, to give effect to the Transaction each Assignor wishes to transfer to PHIVCO-2 LLC., a Delaware corporation with registered number 4731422 (the "Assignee"), and the Assignee desires to acquire and assume from each Assignor, such right, title and interest as each Assignor may have in and to the Intellectual Property Rights listed on Appendix A;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Assignor does hereby sell, transfer, convey and assign to the Assignee such entire right, title and interest as it may have in and to:

- (I) the Intellectual Property Rights listed on attached Appendix A;
- (II) in the case of the patents and patent applications listed on Part 1 of Appendix A, such right title and interest it may have in any patents issuing therefrom, and any continuations, confirmations, divisionals, re-examinations, reissues, revalidations, registrations, supplemental protection certificates or extensions of term, including patent term restoration of any of the foregoing patents and applications and all foreign counterparts thereof and including such right, title and interest as it may have in the inventions covered by the claims of such patents and patent applications (collectively, the "Assigned Patents");

- (III) in the case of the trade marks and trade mark applications listed in Part 2 of Appendix 1, such right title and interest it may have in the goodwill of the business connected with the use of the trade marks and applications and symbolized thereby; and
- (IV) such right title and interest as it may have to sue and recover for any future infringement, damage or injury to any of the Intellectual Property Rights, and for any past infringement, damage or injury to any of the Intellectual Property Rights by any third parties, and collect profits or damages with respect to the same,

the same to be held and enjoyed by Assignee, for its own use and behalf and the use and behalf of its successors and assigns, to the full end of the term or terms for which such Intellectual Property Rights may be granted as fully and entirely as the same would have been held and enjoyed by each Assignor had this sale and assignment not been made.


Each Assignor listed as the registered holder of (A) such patent or patent applications and (B) such trade mark and trade mark applications hereby authorizes and requests the Commissioner or Director of Patents and Trademarks of the United States and any official of any country foreign to the United States whose duty it is to issue patents or trade marks, to issue and transfer the relevant Intellectual Property Rights to Assignee, its successors and assigns, in accordance with the terms of the assignment, or otherwise as Assignee may direct.

This Assignment is binding on each Assignor, its successors and assigns, and will inure to the benefit of Assignee, its successors and assigns. Nothing in this instrument, express or implied, is intended or shall be construed to confer upon, or give to, any person, corporation or entity other than Assignee, its successors and assigns, any remedy or claim under or by reason of this instrument, or any terms, covenants or conditions hereof, and all the terms, covenants and conditions in this instrument shall be for the sole and exclusive benefit of Assignee and its successors and assigns.


The Assignee acknowledges that the Assignor gives no representation, warranty, indemnity or guarantee in respect of any of the Intellectual Property Rights listed on Appendix A or ancillary rights assigned hereunder and each Assignor's rights in and to the Intellectual Property Rights are assigned on an 'as is' basis. This is without prejudice to the provisions of any other agreement implementing the Transaction.

IN WITNESS WHEREOF, each Assignor and the Assignee has caused this Assignment to be executed as of the date written below.


Pharmacia & Upjohn Company LLC
acting by its attorney

By: 
Name: KATHERINE YANG
Title: ATTORNEY-IN-FACT
Date:

Agouron Pharmaceuticals Inc.
acting by its attorney

By: 
Name: ANDREW J. MURATORE
Title: ATTORNEY-IN-FACT
Date:

PHIVCO-2 LLC (as Assignee)
acting by its attorney

By: 
Name: ANDREW J. MURATORE
Title: MANAGER
Date:

APPENDIX A

PART I - PATENTS AND PATENT APPLICATIONS

PC 29066'

Patent Number	Application Number	Title	Proprietor	Country
654808	71732/91	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Australia
654808	71732/91	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Australia
E142621	EP0507861	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Austria
EP0507861	91902628.6	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Belgium
2071529	2071529	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Canada
EP0507861	91902628.6	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Denmark
EP0507861	91902628.6	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	European Patent Convention
EP0507861	91902628.6	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	France
P69028552.3-08	EP0507861	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Germany
EP0507861	91902628.6	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Great Britain
960403026	EP0507861	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Greece
HK1002235	GB0507861	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Hong Kong
211241	P/P00412	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Hungary

Agouron Pharmaceuticals, Inc. has a beneficial interest in the patents and patent applications listed under PC 29066 which is also assigned under this agreement.

Patent Number	Application Number	Title	Proprietor	Country
EP0507861	91902628.6	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Italy
2079522	502810/1991	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Japan
179637	92-701536	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Korea South
10264	P-93-292	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Latvia
EP0507861	91902628.6	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Luxembourg
189647	92.03454	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Mexico
EP0507861	91902628.6	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Netherlands
2099335	5011431.04	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Russian Federation
2093090	EP0507861	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Spain
EP0507861	91902628.6	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Sweden
EP0507861	91902628.6	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	Switzerland
5489593	08/349694	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	United States
5563142	08/198428	Method Of Treating HIV-1 Infected Individuals With Indoles	Pharmacia & Upjohn Company	United States

PC 29265²

Patent Number	Application Number	Title	Proprietor	Country
693939	35136/95	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	Australia
E207481	EP0755393	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	Austria
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	Belgium
2184598	2184598	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	Canada
40.952	561-95	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	Chile
287164	PV2942-96	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	Czech Republic
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	Denmark
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	European Patent Convention
111364	964114	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	Finland
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	France
P69523447.1-08	EP0755393	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	Germany
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	Great Britain
20020400223	EP0755393	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	Greece
	P9602857	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	Hungary
	P-950621	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	The Upjohn Company	Indonesia
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridinyl]	Pharmacia & Upjohn Company	Ireland

² Agouron Pharmaceuticals, Inc. has a beneficial interest in the patents and patent applications listed under PC 29265 which is also assigned under this agreement.

Patent Number	Application Number	Title	Proprietor	Country
113162	113162	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Israel
19240/BE/2002	EP0755393	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Italy
3817261	526952/1995	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Japan
364941	96-705760	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Korea South
12957	P-02-186	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Latvia
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Lithuania
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Luxembourg
MY-116830-A	P19500766	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Malaysia
217492	964831	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Mexico
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Monaco
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Netherlands
282211	282211	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	New Zealand
310024	19964386	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Norway
1-1995-50171	50171	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	The Upjohn Company	Philippines
180776	P-316688	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Poland
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Portugal
2136677	96119978	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Russian Federation
EP0755393	P9530556	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4-[3-(1-methylethylamino)-2-pyridiny]	Pharmacia & Upjohn Company	Slovenia

Patent Number	Application Number	Title	Proprietor	Country
95/2815	95/2815	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridiny	Pharmacia & Upjohn Company	South Africa
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridiny	Pharmacia & Upjohn Company	Spain
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridiny	Pharmacia & Upjohn Company	Sweden
EP0755393	95911842.3	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridiny	Pharmacia & Upjohn Company	Switzerland
NI-115996	84102592	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridiny	The Upjohn Company	Taiwan
14553	26031	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridiny	Pharmacia & Upjohn Company	Thailand
6452007	08/732254	Novel Crystal Forms Of 1-[5-methanesulfonamidoyl]-2-carb-onyl]-4- [3-(1-methylethylamino)-2-pyridiny	Pharmacia & Upjohn Company	United States

PC 29615³

Patent Number	Application Number	Title	Proprietor	Country
753241	42134/99	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Australia
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Austria
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Belgium
	P19910481-4	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Brazil
2328703	2328703	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Canada
ZL99806231.6	99806231.6	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	China P.R.
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Cyprus
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Denmark
4311	200100024	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Eurasian Patent Convention
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	European Patent Convention
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Finland
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	France
69934582	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Germany
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Great Britain
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Greece
HK 1036417	1107510.5	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Hong Kong
	P0102206	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Hungary
	702/MUMNP/2003	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	India
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Ireland
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Italy
	2000-553039	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Japan
724016	10-2000-7013985	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Korea South
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Luxembourg
215176	12294	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Mexico
	2003/006002	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Mexico
	2003/001014	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Mexico
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Netherlands
508762	508762	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	New Zealand
PAT-200163	P344328	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Poland
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Portugal
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Romania

³ Agouron Pharmaceuticals, Inc. has a beneficial interest in the patents and patent applications listed under PC 29615 which is also assigned under this agreement.

Patent Number	Application Number	Title	Proprietor	Country
4311	200100024	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Russian Federation
P-76422	200005818-0	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Singapore
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Slovenia
20006090	20006090	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	South Africa
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Spain
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Sweden
1083885	99925951.8	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	Switzerland
6177101	11/487554	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	United States
7108864	09/327135	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	United States
	09/656364	Delavirdine Tablet Formulation	Pharmacia & Upjohn Company	United States

PC 33306⁴

Patent Number	Application Number	Title	Proprietor	Country
	11/770698	Pyrazole Derivatives As Cytochrome P450 Inhibitors	Agouron Pharmaceuticals, Inc.	United States

⁴ Pfizer Limited has a beneficial interest in the patents and patent applications listed below under PC33306 which is not assigned under this agreement.

PHIVED-2 LLC

PART 2 - TRADE MARK AND TRADE MARK APPLICATIONS

DELA VIRDINE TRADEMARKS

Mark	Country	Status	Class	Owner	App. No.	App. Date	Reg. No.	Reg. Date	Renewal Date
RESCRIPTOR	Algeria	Registered	5	Pharmacia & Upjohn Company LLC	1159/92	22/09/1992	45545	22/09/1992	11/06/2012
RESCRIPTOR	Angola	Registered	5	The Upjohn Company	3284	07/09/1993	003284	07/09/1993	07/09/2003
RESCRIPTOR	Argentina	Registered	5	Pharmacia & Upjohn Company LLC	1857040	23/09/1992	1505183	28/02/1994	04/06/2014
RESCRIPTOR	Bahamas	Registered	3	The Upjohn Company	15478	29/09/1992	15478	29/09/1992	29/09/2020
RESCRIPTOR	Bangladesh	Registered	5	The Upjohn Company	36242	22/10/1992	36242	22/10/1992	22/10/2014
RESCRIPTOR	Barbados	Registered	5	The Upjohn Company		19/08/1998	817715	19/08/1998	19/08/2008
RESCRIPTOR	Bolivia	Registered	5	Pharmacia & Upjohn Company LLC		07/10/1992	56567C	31/05/1994	31/05/2014
RESCRIPTOR	Bosnia-Herzegovina	Filed	5	Pharmacia & Upjohn Company LLC	BAZ0813245A	04/09/2008			
RESCRIPTOR	Brazil	Registered	510	Pharmacia & Upjohn Company LLC	816933855	06/10/1992	816933855	28/06/1994	28/06/2014
RESCRIPTOR	Canada	Registered		Pharmacia & Upjohn Company LLC	713878	30/09/1992	TMA501899	06/10/1998	06/10/2013
RESCRIPTOR	Colombia	Registered	5	Pharmacia & Upjohn Company LLC	368886	07/10/1992	171345	30/12/1994	30/12/2014
RESCRIPTOR	Congo	Registered	5	The Upjohn Company	203/EXT/92	19/11/1992	304192	19/11/1992	19/11/2012
RESCRIPTOR	Dominican Republic	Registered	11	Pharmacia & Upjohn Company LLC		02/10/1992	76243	15/12/1992	15/12/2012
RESCRIPTOR	Gambia	Registered	5	Pharmacia & Upjohn Company LLC	21/93	05/01/1993	21/93	05/01/1993	05/01/2021
RESCRIPTOR	Georgia	Registered	5	Pharmacia & Upjohn Company LLC	501003	30/07/1993	4932	03/04/1997	03/04/2017
RESCRIPTOR	Iran	Registered	5	Pharmacia & Upjohn Company	111368	13/02/1994	72579	13/02/1994	13/02/2014
RESCRIPTOR	Japan	Registered	5	Pharmacia & Upjohn Company LLC	296906/92	06/10/1992	3093353	30/11/1995	30/11/2015
RESCRIPTOR	Lebanon	Registered	5	Pharmacia & Upjohn Company LLC	59004	05/10/1992	59004	05/10/1992	05/10/2022

Mark	Country	Status	Class	Owner	App. No.	App. Date	Reg. No.	Reg. Date	Renewal Date
RESCRIPTOR	Liberia	Registered	5	Pharmacia & Upjohn Company LLC		06/04/1993	6493/845	06/04/1993	08/04/2023
RESCRIPTOR	Macao	Registered	5	Pharmacia & Upjohn Company LLC	13103	23/11/1993	13103	08/06/1994	08/06/2004
RESCRIPTOR	Moldova	Registered	5	Pharmacia & Upjohn Company LLC	003650	20/12/1994	3921	20/12/1994	20/12/2014
RESCRIPTOR	Morocco	Registered	5	Pharmacia & Upjohn Company LLC		02/10/1992	49620	02/10/1992	02/10/2012
RESCRIPTOR	Namibia	Registered	5	Pharmacia & Upjohn Company LLC	92/1032	05/10/1992	92/1032	05/10/1992	05/10/2012
RESCRIPTOR	Nepal	Registered	5	The Upjohn Company		21/01/1996	11306/052	21/01/1996	21/01/2010
RESCRIPTOR	New Zealand	Registered	5	Pharmacia & Upjohn Company LLC	74/264307	22/09/1992	221621	09/04/1999	09/04/2013
RESCRIPTOR	Nicaragua	Registered	5	Pharmacia & Upjohn Company LLC	219	29/01/1993	24745	11/01/1994	10/01/2014
RESCRIPTOR	Nigeria	Registered	5	Pharmacia & Upjohn Company LLC	19215588	07/10/1992	58334	07/10/1992	07/10/2013
RESCRIPTOR	O.A.P.I.	Registered	5	Pharmacia & Upjohn Company LLC	81865	09/10/1992	32195	09/10/1992	09/10/2012
RESCRIPTOR	Pakistan	Registered	5	Pharmacia & Upjohn Company LLC	117511	20/10/1992	117511	20/10/1992	20/10/2014
RESCRIPTOR	Philippines	Registered	5	Pharmacia & Upjohn Company LLC	83862	16/12/1992	4/1992/083802	08/07/2004	08/07/2014
RESCRIPTOR	Sierra Leone	Filed	3	The Upjohn Company		20/10/1992			
RESCRIPTOR	Sri Lanka	Registered	5	Pharmacia & Upjohn Company LLC	64872	07/10/1992	64872	07/10/1992	07/10/2012
RESCRIPTOR	Switzerland	Registered	5	Pharmacia & Upjohn Company LLC	7010	28/09/1992	401347	28/09/1992	28/09/2012
RESCRIPTOR	Trinidad & Tobago	Registered	3	Pharmacia & Upjohn Company LLC	NONE	09/04/1992	21098	09/04/1992	08/04/2016
RESCRIPTOR	Tunisia	Registered	5	Pharmacia & Upjohn Company LLC	NONE	02/10/1992	EE921058	02/10/1992	02/10/2017
RESCRIPTOR	United Arab Emirates	Registered	5	Pharmacia & Upjohn Company LLC	2901	23/10/1993	3360	11/12/1995	23/10/2013
RESCRIPTOR	United States	Registered	5	Pharmacia & Upjohn Company LLC	74/264307	09/04/1992	1926253	10/10/1995	10/10/2015
RESCRIPTOR	Uzbekistan	Registered	5	Pharmacia & Upjohn Company LLC	1638/T3	18/10/1993	3740	18/10/1993	18/10/2013

Mark	Country	Status	Class	Owner	ADD. No.	ADD. Date	Reg. No.	Reg. Date	Renewal Date
RESCRIPTOR	Uzbekistan	Registered	5	Pharmacia & Upjohn Company LLC	163173	18/10/1993	3796	18/10/1993	18/10/2013
RESCRIPTOR	Venezuela	Registered	5	Pharmacia & Upjohn Company	1992-021869	29/09/1992	P-176606	05/06/1995	05/06/2010
RESCRIPTOR IN KATANANA	Japan	Registered	5	Pharmacia & Upjohn Company LLC	29690792	06/10/1992	3093354	30/11/1995	30/11/2015

APPENDIX B
ASSIGNORS

**Pharmacia & Upjohn Company LLC (previously known as Pharmacia & Upjohn Company
and The Upjohn Company)**

Agouron Pharmaceuticals Inc.